This study was aimed to analyze the prognostic factors of the patients with chronic myeloid leukemia (CML). Survival curve and survival rate of 204 patients with CML were estimated with Kaplan-Meier method and Logrank respectively. Univariate and multivariate analysis of prognostic factors carried out by Cox's regression model. The Sokal and Hasford score were used to discriminate the relative risk of Hu and IFN group. The results showed that among the 204 patients, the median survival time was 50 (32-65) months, and 5 year survival rate was 32.3% (95% CI, 23.7%-42.6%). The median survival times of IFN and Hu group were 56 (41-67) and 41 (19-56) months, and 5 year survival rates were 45.4% (95% CI, 37.5%-54.2%) and 26.8% (95% CI, 21.6%-33.3%) (P < 0.001) respectively. From the Cox stepwise regression model, Ph chromosome negative, high LDH, low Hct, percentage of peripheral blood basophils > or = 10%, marrow blasts + promyelocytes > or = 10% and presence of nucleated RBCs was associated with poor prognosis, and the treatment also played an important role in CML. According to the Sokal score, the high, intermediate and low risk rates of Hu group were 72.9%, 21.5% and 5.6%, the median survival time reached 34 (23-49) months, 43 (32-58) and 50 (38-62) months respectively; while censored by the Hasford score, the high, intermediate and low risk rates of IFN group were 17.6%, 25.1% and 57.3% respectively, the median survival time was 44 (33-57), 56 (45-70) and 66 (52-76) months respectively. It is concluded that Ph chromosome, concentration of LDH, percentage of Hct, peripheral blood basophils, marrow blasts, promyelocytes, presence of nucleated RBCs and treatment are the most important prognostic factors for CML. The Sokal score can not discriminate the relative risk of Hu group well, while the Hasford score can discriminate the relative risk of IFN group.
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; drug therapy ; mortality ; Middle Aged ; Multivariate Analysis ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; methods ; Survival Rate ; Treatment Outcome

Objective:To investigate the effects of miR-217 on proliferation and adriamycin sensitivity of acute myeloid leukemia(AML)cells.Methods:The mimic NC and miR-217 mimic vectors were constructed and transfected into HL-60 cells,and transfection efficiency was detected by qPCR.The cells were treated with different concentrations of adriamycin for 24 h and 48 h.CCK-8 assay was used to detect the chemical sensitivity of adriamycin and screen the optimal concentration and time of adriamycin treatment.Cells were divided into control group,mimic NC group,miR-217 mimic group,adriamycin group and miR-217 mimic+adriamycin group.Apoptosis was detected by flow cytometry,and the expressions of miR-217,PI3K and Akt3 were detected by qPCR.Western blot was used to detect the expression of PI3K/Akt pathway proteins PI3K,Akt3 and apoptosis proteins Bcl-2,Bax,and double luciferase was used to verify the relationship between miR-217 and Akt3.Results:MiR-217 mimic could enhance the sensitivity of HL-60 cells to adriamycin.The optimal concentration and treatment time of adriamycin were 160 ng/ml and 48 h,respectively.Compared with control group,apoptosis rate,miR-217 and Bax protein levels were significantly increased in miR-217 mimic and adriamycin groups(P＜0.01),while Bcl-2 protein,PI3K,Akt3 mRNA and protein levels were significantly decreased(P＜0.01).Compared with adriamycin group,apoptosis rate,miR-217 and Bax protein levels were significantly increased in miR-217 mimic+adriamycin group(P＜0.01),while Bcl-2 protein,PI3K,Akt3 mRNA and protein levels were significantly decreased(P＜0.0 1).Dual luciferase assay showed that there was a targeted regulatory relationship between miR-217 and Akt3.Conclusion:MiR-217 regulates the PI3K/Akt pathway targeting Akt3,inhibits cell proliferation,promotes cell apoptosis and enhances the sensitivity of adriamycin to AML cells.

OBJECTIVE: To investigate the effect of long non-coding RNA LINC01268 on apoptosis of acute myeloid leukemia (AML) cells and related mechanisms. METHODS: The expression levels of LINC01268 and miR-217 in peripheral blood samples from AML patients and AML cell lines HL-60 and KG-1 were detected by qRT-PCR. HL-60 cells were divided into pcDNA3.1-NC, pcDNA3.1-LINC01268, si-NC, si-LINC01268, miR-NC, miR-217 mimics, si-LINC01268 + inhibitor-NC and si-LINC01268+ miR-217 inhibitor groups. The mRNA expressions of LINC01268 and miR-217 were detected by qRT-PCR. The targeting relationship between LINC01268 and miR-217 was detected by dual-luciferase reporter assay. Cell viability was detected by CCK-8 assay. Cell cycle distribution and apoptosis were detected by flow cytometry. The expression of cell cycle and apoptosis-related proteins p21, Bcl-2, Bax, caspase-3 and PI3K/AKT signaling pathway-related proteins were detected by Western blot. RESULTS: The expression of LINC01268 in peripheral blood samples of AML patients and AML cell lines HL-60 and KG-1 was increased (P < 0.05), and the expression of miR-217 was decreased (P < 0.05). Compared with si-NC group and miR-NC group, the viability of HL-60 cells was decreased in si-LINC01268 group and miR-217 mimics group (P < 0.05), the proportion of cells in G₁ phase and apoptosis rate were increased (P < 0.05), the protein expression levels of p21, Bax and caspase-3 were increased (P < 0.05), while the protein expression level of Bcl-2 was decreased (P < 0.05). LINC01268 targeted and negatively regulated the expression of miR-217, and inhibiting the expression of miR-217 partially reversed the effects of LINC01268 interference on the viability, cell cycle and apoptosis of HL-60 cells. Interference with LINC01268 could inhibit the activity of PI3K/AKT signaling pathway. Inhibiting the expression of miR-217 could partially reverse the inhibition of LINC01268 interference on PI3K/AKT signaling pathway. CONCLUSION LINC01268 is highly expressed and miR-217 is lowly expressed in AML cells. LINC01268 can promote the activity of PI3K/AKT signaling pathway, increase the survival rate and inhibit the apoptosis of AML cells by targeting miR-217 expression.
Humans ; Apoptosis ; bcl-2-Associated X Protein/metabolism* ; Caspase 3 ; Cell Line, Tumor ; Cell Proliferation ; Leukemia, Myeloid, Acute/metabolism* ; MicroRNAs/metabolism* ; Phosphatidylinositol 3-Kinases/metabolism* ; Proto-Oncogene Proteins c-akt/metabolism* ; RNA, Long Noncoding/genetics*

Objective To compare the influence of the doctor-nurse collaborating model and conventional nursing on quality of life (QOL) of esophageal cancer patients undergoing concurrent chemoradiotherapy.Methods Totals of 105 eligible patients were randomly assigned to receive the doctor-nurse collaborating model group (study group,n =55) and conventional nursing group (control group,n =50).European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (QLQ-C30) was used to investigate them before intervention and after 1 month of the intervention.Results After implementing the doctor-nurse collaborating model,45 cases in study group and 32 cases in the control group completed established chemoradiotherapy,and the difference was statistically significant (x2 =4.252,P ＜ 0.05).One month later,the function items of QLQ-C30 were decreased in both groups,and the level of control group was more obviously.And the symptom items of two groups were increased after the intervention,the pain score in study group was significantly lower than that of control group [(35.4 ± 16.2) vs (42.8 ± 19.0) ; t =2.147,P ＜ 0.05].Conclusions The doctor-nurse collaborating model has positive effects on the QOL of patients with esophageal cancer,and increases their compliance.